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Mucosal-associated invariant T (MAIT) cells are innate-like T lymphocytes with potent antibacterial 
reactivity. In this study, we investigated whether MAIT cells also contribute to immunity against 
influenza A viruses. Compared with those who succumbed, hospitalized patients who recovered from 
severe avian H7N9 influenza infection had higher numbers of MAIT cells. Subsequent in vitro 
analysis established that MAIT cells from healthy donors are indirectly activated by influenza 
infection via an IL-18–dependent (but not IL-12–dependent) mechanism requiring the involvement of 
CD14+ monocytes. Our findings highlight the potential for MAIT cells to promote protective 
immunity in human influenza 
 
Abstract 
Mucosal-associated invariant T (MAIT) cells are innate-like T lymphocytes known to elicit potent 
immunity to a broad range of bacteria, mainly via the rapid production of inflammatory cytokines. 
Whether MAIT cells contribute to antiviral immunity is less clear. Here we asked whether MAIT cells 
produce cytokines/chemokines during severe human influenza virus infection. Our analysis in patients 
hospitalized with avian H7N9 influenza pneumonia showed that individuals who recovered had 
higher numbers of CD161+Vα7.β+MAIT cells in peripheral blood compared with those who 
succumbed, suggesting a possible protective role for this lymphocyte population. To understand the 
mechanism underlying MAIT cell activation during influenza, we cocultured influenza A virus (IAV)-
infected human lung epithelial cells (A549) and human peripheral blood mononuclear cells in vitro, 
then assayed them by intracellular cytokine staining. Comparison of influenza-induced MAIT cell 
activation with the profile for natural killer cells (CD56+CD3−) showed robust up-regulation of IFNȖ 
for both cell populations and granzyme B in MAIT cells, although the individual responses varied 
among healthy donors. However, in contrast to the requirement for cell-associated factors to promote 
NK cell activation, the induction of MAIT cell cytokine production was dependent on IL-18 (but not 
IL-12) production by IAV-exposed CD14+monocytes. Overall, this evidence for IAV activation via 
an indirect, IL-18–dependent mechanism indicates that MAIT cells are protective in influenza, and 
also possibly in any human disease process in which inflammation and IL-18 production occur. 
Human mucosal associated invariant T (MAIT) cells are innate-like T lymphocytes characterized by a 
semi-invariant T-cell receptor (TCR), Vα7.β (TRAV 1–β), paired with variable ȕ-chains (1, 2). In 
adult blood, MAIT cells are further defined by constitutive, high-level expression of the IL-18 
receptor (IL-18R), the promyelocytic leukemia zinc finger (PLZF) transcription factor, and the 
CD161 C-type lectin (3, 4). Potently reactive to metabolites of vitamin B2 biosynthetic intermediates 
(5, 6) that bind to the non-classical MHC-1–related (MR1) proteins, MAIT cells are robustly activated 
to produce cytokines and chemokines [IFNȖ, TNF, granzyme B (GzmB), IL-17A, and IL-22] 
following exposure to microbes (Salmonella, Escherichia coli, and Candida albicans) that possess 
riboflavin pathways (4, 7). Given the prominence of MAIT cells in human peripheral blood (1–10%) 
and in tissue sites of inflammation, including the gut and lung (3, 8, 9), there is a need to define their 
role in immunity, with the situation for viral infections remaining relatively unclear. 
During HIV-1 infection, numbers of MAIT cells, as defined by coexpression of CD161 and Vα7.β, 
are reduced (10⇓–12), and their numbers in the periphery are not restored after antiretroviral drug 
treatment, although it is thought that microbial translocation may drive chronic MAIT cell activation 
(10, 11). Moreover, with the advent of MR1 tetramers to detect MAIT cells, more recent studies have 
confirmed the loss of MAIT during chronic HIV infection (1, 12). To date, only murine studies in 
Vα19Vȕ6 transgenics have demonstrated that MAIT cells, as measured by CD69 up-regulation in 
vitro, are not activated by coculture with antigen-presenting cells infected with a range of viruses, 
including Sendai virus, Newcastle disease virus, and herpes simplex virus (8). Stimulation with IL-12 
and IL-18 can, however, induce IFNȖ production in human MAIT cells in an MR1-independent 
manner (13, 14). 
Because MAIT cells are both pro-inflammatory and potentially activated by IL-12 and IL-18, the 
possibility that they play a positive role in respiratory virus infections seems plausible. In a recent 
report of a hospitalized patient cohort, we established that a spectrum of innate and antigen-specific 
responder cells is recruited during the course of severe H7N9 influenza pneumonia (15). Our further 
analysis from this study of the CD161+Vα7.β+ MAIT cells recovered ex vivo from these patients 
showed that the numbers were 2.5-fold greater in those who survived, suggesting that MAIT cells 
may indeed contribute to protection. 
To understand how MAIT cells are activated during early IAV infection, we established an in vitro 
coculture system with IAV-infected human lung epithelial cells and normal human peripheral blood 
mononuclear cells (PBMCs). Using a 12–14 parameter flow cytometry panel to measure innate and 
adaptive responses, which included a MR1 tetramer loaded with 5-(2-oxopropylideneamino)-6-D-
ribitylaminouracil (MR1-5-OP-RU), we found that IAV infection of epithelial cells induced robust, 
early IFNȖ production in MAIT cells, defined as MR1-5-OP-RU tetramer+Vα7.β+ or by the surrogate 
MAIT cell markers CD161+Vα7.β+. Antibody blocking indicated that this effect was mediated by IL-
18, but not by IL-12. Furthermore, CD14+ monocytes were also required for MAIT cell activation 
during coculture, most likely as a source of inflammatory mediators. The present analysis indicates 
that MAIT cells may indeed help protect against the most severe consequences of human influenza 
virus infection. 
RESULTS 
Reduced Numbers of MAIT Cells in Fatal Influenza. 
We recently investigated the population dynamics of CD8+ T-cell responses in hospitalized H7N9 
patients with severe influenza pneumonia (15). Given that the CD8+ Vα7.β+ subset is likely to 
include both MR1-restricted and –non-restricted MAIT cells (1), we performed a retrospective 
comprehensive analyses using CD161 in combination with TCR Vα7.β to determine whether the 
MAIT cell response varies in hospitalized patients with different clinical outcomes. Comparing the 
numbers of CD161+Vα7.β+ T cells in stored PBMCs between patients who recovered and those with 
a fatal outcome across all available time points after disease onset (n = 16 patients; days 6–34) 
revealed significantly lower numbers of MAIT cells in the fatal cases (P = 0.014, nonparametric one-
way ANOVA) (Fig. 1A). However, the comparable peripheral blood counts for 
CD161+Vα7.β+ MAIT cells in the survivors (mean age, 68 y) and in healthy controls (mean age, 70 
y) indicates that MAIT cell activation may be markedly reduced in fatal influenza infection. Another 
possibility is that the MAIT cells are recruited to, and perhaps destroyed at, the site of pathology. 
 
To gain insight into the dynamics of MAIT cell involvement during the course of severe influenza 
disease, we analyzed CD161+Vα7.β+ T cells at multiple time points after disease onset: days 6–12, 
days 13–20, and days 21–35 (Fig. 1B). As in our previous study (15), we subdivided patients 
hospitalized at ∼days 6–8 after the onset of symptoms according to their recovery rates, ranging from 
early (R1: days 14–18 after disease onset) to delayed (R2: days 21–27, R3: days 31–35), vs. a fatal 
outcome. Our data show that during the first week of hospitalization (days 6–12), only the patients 
who recovered early from H7N9 disease (R1) had higher MAIT cell numbers than seen in the fatal 
group (P < 0.05) (Fig. 1 B, i and C). Interestingly, there was a trend (albeit insignificant) toward 
higher numbers of MAIT cells in delayed recovery group R3 during the last week of hospitalization 
(days 21–35) (Fig. 1 B, iii), which was not observed in group R2, which had a shorter hospital stay. 
This finding might be linked to the kinetics of MAIT cells before the recovery during prolonged 
hospitalization. Further experiments with a larger patient cohort and more frequent assessment time 
points are needed to better understand the kinetics of MAIT cells during prolonged severe influenza 
disease. Our present findings suggest that MAIT cells may contribute to recovery from influenza, and 
highlight the importance of understanding MAIT cell dynamics in patients with severe viral 
pneumonia, which of course are influenced by the cells’ profiles of migration to (and from) the site of 
inflammatory pathology. 
 
IAV Infection in PBMC Cocultures Induces IFNγ Production by MAIT Cells. 
The lung epithelial cells that are the primary sites of productive IAV infection make inflammatory 
mediators that promote the influx of innate and adaptive immune cells at the site of infection (16). To 
understand how MAIT cells are activated during IAV infection, we established a coculture system in 
which A549 cells (a human lung type 2 epithelial cell line) were infected with the H1N1 and H3N2 
IAVs (Fig. 2A). These cells (>80% infected at 10 h; Fig. 2C) were then cocultured with human 
PBMCs for 10 h in the presence of the protein export inhibitor brefeldin A (last 6 h of culture), 
allowing the production (and intracellular retention) of virus-induced soluble or cell-associated factors 
(Fig. 2A). An analysis of intracellular cytokine staining (ICS) for IFNȖ in the MAIT, natural killer 
(NK), and Ȗδ T-cell subsets (Fig. 2B and Fig. S1) from PBMCs incubated with control (previously 
incubated in allantoic fluid) and H1N1/H3N2-infected A549 cells established that the IAV exposure 
induced IFNȖ production in the MAIT cells (8.6 ± 7.5%; n = 22), at levels (Fig. 2 D and E) 
comparable to those found for Ȗδ T cells (7 ± 7.5%; n = 22) and NK cells (20.8 ± 13.5%; n= 22). 
Indeed, significantly higher up-regulation of IFNȖ in MAIT, NK, and Ȗδ T cells was found compared 
with classical MHC-restricted “helper” and “killer” T cells (P ≤ 0.001; Fig. 2E), reflecting that IFNȖ 
production in the conventional CD4+ or CD8+ T-cell subsets is antigen-specific. 
 
Given the robust IFNȖ production by MAIT, NK, and Ȗδ T cells, we next evaluated for any correlation 
between the high frequency of MAIT cells producing IFNȖ during influenza infection and IFNȖ 
production in NK or Ȗδ T cells within the same donor. Indeed, we observed strong correlations in 
IFNȖ production between MAIT/NK (P < 0.01; r = 0.569, Spearman rank correlation) and MAIT/Ȗδ T 
cells (P < 0.0001; r = 0.888) (Fig. S2), suggesting that overall, these three subsets respond mutually 
during IAV infection. This does not imply that MAIT cells are dependent on NK or Ȗδ T cells to 
produce IFNȖ, however. 
 
Coculture of PBMCs with IAV-infected A549 cells did not result in significant expression of CD107a 
(minimally on NK cells), a known marker of degranulation for NK, MAIT, and Ȗδ T cells (Fig. 2D), 
or TNF production (Fig. S3). However, the MAIT cells, and not the conventional CD8+/CD4+ T-cell 
subsets, up-regulated CD69 surface expression during coculture with IAV-infected A549 cells (Fig. 
2F). Significant up-regulation of intracellular GzmB was also observed (***P < 0.001; n = 12). We 
further suggest that GzmB is an early marker of MAIT cell activation (Fig. 2G), and also that the 
surrogate MAIT cell markers CD161 and Vα7.β identify the IFNȖ-producing MR1-5-OP-RU-
Tet+Vα7.β+ after early IAV infection (Fig. S4). 
 
MAIT Cell Activation Is Not Abrogated by MR1-Blocking Antibody. 
To understand MAIT cell activation during IAV infection, we first asked whether MAIT cell IFNȖ 
production after exposure to IAV-infected epithelial cells is MR1-dependent. Several riboflavin 
derivatives from microbial species, including Escherichia coli, are presented by MR1 (5, 6, 17, 18); 
however, the addition of α-MR1–blocking monoclonal antibody (clone 26.5) to the IAV coculture 
system did not reduce the relative expression levels of IFNȖ compared with coculture of PBMCs with 
1% paraformaldehyde-fixed E. coli, where α-MR1 is known to inhibit cytokine production in MAIT 
cells (by approximately twofold) (Fig. 3A). This suggests that the activation of MAIT cells during 
IAV coculture is MR1-independent 
 
In the absence of other PBMC subsets, FACS-purified CD161+Vα7.β+CDγ+ MAIT cells cultured 
with IAV-infected A549 cells for 10 h in the presence of BFA did not make IFNȖ (Fig. 3B). However, 
comparably enriched CD56+CD3− NK cells up-regulated IFNȖ production above background 
(uninfected A549) during direct coculture with IAV-infected A549 cells (Fig. 3C). Taken together, 
our results indicate that the activation of MAIT cells during IAV infection requires soluble 
inflammatory factors and/or accessory cells found in the PBMC pool. 
 
Soluble Factors in Culture Supernatants and Their Role in MAIT Cell Activation. 
To understand whether MAIT cells are activated via the IAV-induced inflammatory milieu, we 
assayed for cytokines/chemokines in the culture supernatants by a cytometric bead array (CBA) 
analysis. After IAV infection, but in the absence of PBMCs, the A549 cells up-regulated chemotactic 
molecules for monocytes and lymphocytes, namely MCP-1 and RANTES (Fig. 3 D, i). Elevated 
levels of IL-6, MCP-1, MIP1α/ȕ, and IL-1ȕ were observed during IAV infection, but these were 
present in uninfected controls as well (Fig. 3 D, ii). Type I IFN (IFNα) production was, as might be 
expected, limited to the IAV-exposed cells. Moreover, when both IAV-infected A549 cells and 
PBMCs were present, TNF, IFNȖ, and GzmB were detected early in the culture supernatants (Fig. 
3 D, iii). 
To examine whether influenza-induced soluble mediators can directly activate MAIT cells to produce 
IFNȖ, we transferred supernatants from uninfected and IAV-infected cocultures to autologous PBMCs 
and measured IFNȖ responses in the various lymphocyte subsets by ICS (Fig. 4A). We found that 
supernatants from uninfected A549-PBMC cocultures contained inflammatory mediators (Fig. 3D) 
that did not activate MAIT cells (Fig. 4 B, i, Middle). In contrast, when the supernatants from the IAV 
cocultures were added to autologous PBMCs, they induced robust production of IFNȖ in MAIT cells 
(Fig. 4 B, i and ii), although MAIT cell GzmB expression was affected variably (Fig. 4 B, ii). 
Conversely, the up-regulation of IFNȖ in NK cells was significantly reduced when cocultured with the 
IAV supernatants, indicating that NK cells require both accessory cells and inflammatory mediators 
for optimal induction during IAV infection (Fig. 4 B, iii). Taken together, these data suggest that 
MAIT cells are activated by soluble inflammatory mediator(s) induced during IAV infection. 
 
IL-18–Dependent Activation of MAIT Cells During IAV Infection. 
Earlier studies (14, 19) have shown that MAIT cells respond robustly to cytokine-driven stimulation 
(IL-18, IL-12, and IL-7) and constitutively express high surface levels of the IL-18 and IL-12 
receptors (14). Given our findings indicating that MAIT cells make IFNȖ and GzmB when stimulated 
in IAV A549-PBMC cocultures (Fig. 4 A and B), we assessed whether IL-12 and IL-18 are the 
soluble inflammatory mediators driving this process. Indeed, compared with other PBMC subsets, the 
MAIT cells expressed higher surface levels of the IL-18R (Fig. 4C). Subsequent addition of both αIL-
18 and αIL-12 to the IAV A549-PBMC cocultures led to an ∼50% reduction in IFNȖ production (48.5 
± 12.5%; n = 4) by MAIT cells (Fig. 4D, second column). This drop in IFNȖ secretion is attributed to 
IL-18 rather than to IL-12 (Fig. 4D, third column; *P < 0.05), because robust IFNȖ production was 
retained for cultures containing only the IL-12 p40/70 blocking antibody (Fig. 4D, fourth column). 
Even so, given that we did not observe a complete reduction in IFNȖ production, our data suggest that 
in addition to IL-18, other inflammatory mediators also may contribute to the up-regulation of IFNȖ 
production during early IAV infection. 
 
CD14+ monocytes are required for MAIT cell activation during IAV coculture. 
It is clear that IAV infection triggers the recruitment and differentiation of monocytes (Fig. 3D) via 
chemotactic cytokines/chemokines (20). Activated monocytes can then serve as a source of 
proinflammatory and antiviral mediators during IAV infection (reviewed in ref. 16). When 
CD14+ monocytes were cocultured with IAV-infected lung epithelial cells, we observed a significant 
increase in TNF production compared with that found after exposure to uninfected epithelial cells 
(Fig. 5A; **P < 0.002). This suggests that monocytes are directly activated by exposure to IAV-
infected epithelium, and in turn contribute to the induction of MAIT cells during influenza. 
 
To examine this possibility, we depleted the CD14+ monocytes (>99%) from PBMCs using magnetic 
beads. In the absence of the CD14+ sets, IFNȖ production in MAIT cells was significantly, although 
not completely, reduced (Fig. 5 B, i and ii; **P < 0.01), although IFNȖ in the NK cells was reduced to 
background levels (Fig. 5 B, i). This indicates that CD14+ monocytes contribute to the activation of 
MAIT cells during coculture, and may provide a source of IL-18 for activation. 
 
Discussion 
Influenza contributes significantly to morbidity and mortality in high-risk groups, including elderly 
persons, young children, pregnant women, and immunocompromised individuals (21, 22). Although 
B cells producing strain-specific neutralizing antibodies are the gold standard of sterilizing immunity, 
they provide little or no protection against newly emerging pandemic IAV strains. Consequently, if 
we are to deal effectively with the threat posed by a novel IAV subtype (or some other emerging 
pathogen), we first need to understand the roles of other arms of innate and adaptive immunity, then 
investigate whether it is possible to manipulate such defense mechanisms. These potential mediators 
of “universal” immunity include nonneutralizing antibodies, cross-reactive IAV-specific T cells, 
neutrophils, macrophages, NK cells, and other “innate-like” T cells (23, 24). Although it is well 
appreciated that classical innate cell types, such as neutrophils, macrophages, and dendritic cells, play 
essential roles in the influenza-specific host response (16), there is a paucity of data on whether, and if 
so how, MAIT cells contribute to antiviral immunity during influenza and other viral infections. 
The present study shows that in the absence of preexisting neutralizing antibodies, the absolute 
numbers of CD161+Vα7.β+ MAIT cells in H7N9-infected patients are higher in patients with severe 
but nonfatal influenza than in those who succumb to this disease. This situation is in contrast to 
chronic viral infections such as HIV, where an ongoing inflammatory process is not characterized by 
any recovery in MAIT cell numbers, even after effective antiretroviral therapy (10, 12). 
Having established a possible correlation with MAIT cell numbers in hospitalized patients with 
H7N9-induced IAV pneumonia of varying severity, we next asked how MAIT cells are activated 
during early influenza infection, using an in vitro model of IAV-infected human lung epithelial cells 
cocultured with PBMCs. Our findings led to the proposal that robust MAIT cell up-regulation of IFNȖ 
and GzmB follows such IAV exposure and is dependent on soluble inflammatory mediators, 
particularly IL-18 (Fig. 5C). Although previous studies with Vα19Vȕ6-Tg mice indicated that a range 
of virus-infected (but not including IAV) macrophages failed to activate MAIT cells in vitro (7), we 
have shown that CD14+monocytes are required for the optimal induction of the MAIT cell response 
in IAV pneumonia. Furthermore, our findings suggest that GzmB is a useful ex vivo marker for 
MAIT cell activation during early IAV infection. 
It is well established that T and NK cells make IFNȖ when cultured in the presence of IL-18, a potent 
proinflammatory cytokine. Indeed, our data demonstrate that IFNȖ production in NK cells is 
modulated in part by IL-18, although we suggest that additional cell-associated factors are needed for 
complete activation. The mechanisms leading to MAIT activation (IFNȖ and GzmB up-regulation) are 
indirect, with the MAIT cells induced predominantly by soluble mediators produced during early IAV 
infection. Earlier work in human PBMCs has shown that IL-18, acting synergistically with IL-12, is 
important for the TLR-driven activation of MAIT cells (14, 25, 26); however, our present analysis 
demonstrates that blocking soluble IL-18 (but not IL-1β singly) abrogates IFNȖ production during 
IAV infection. Similarly, previous studies using murine models of IAV infection have demonstrated 
that IL-18 alone is required for optimal IFNȖ production in CD8+ T cells (27). Although IL-12 was 
not detected in our CBA analyses, the physiological concentration may be below the limit of 
detection. Furthermore, Guo et al. (28) reported that IL-18 (but not IL-12) was readily found in the 
serum of hospitalized H7N9 patients. Indeed, the fact that IL-18 is present at significant levels in the 
peripheral circulation suggests that a “global” activation of MAIT cells may occur in multiple 
peripheral sites in addition to the infected lung. 
Considering that complete abrogation of IFNȖ production was not found consequent to IL-18 
blocking, it is possible that other inflammatory mediators (e.g., MCP-1, TNF, type 1 IFN) in 
supernatants from the IAV-infected cocultures may further activate MAIT cells. These inflammatory 
mediators are characteristic of the “cytokine storm” that can be detected in both bronchiolar lavage 
fluid and serum from hospitalized H7N9 patients (20). Given such potent hypercytokinemia, it could 
prove informative to look more closely at MAIT cells in severe, debilitating viral infections, both in 
patients and in animal models. 
We speculate that monocytes are the source of IL-18 during in vitro coculture, given that depletion of 
this subset from the PBMC pool resulted in a significant abrogation in MAIT IFNȖ up-regulation. 
Recent studies showing TCR-independent MAIT cell induction for PBMCs cultured in vitro with IL-
15 have demonstrated that this activation is dependent on the presence of IL-18–producing monocytes 
(25). Previous studies also have suggested that live IAV infection can promote the differentiation of 
monocytes into dendritic cells (29, 30). Thus, the cytokine/chemokine milieu generated during in vitro 
coculture may promote first monocyte differentiation, then MAIT cell activation during IAV 
infection. In addition, lung epithelial cells express the IL-18 precursor protein (31). Although 
cleavage to the mature form of IL-18 in response to IAV remains unclear, these cells may serve as a 
potential source of IL-18. Further experiments using sensitive detection methods for the active form 
of IL-18 are needed. 
When it comes to functional activity and possible protection, it is clear that, following TCR-mediated 
stimulation and subsequent up-regulation of perforin and GzmB, MAIT cells can kill bacterially 
infected targets. Furthermore, the expression of CD107a, a surrogate marker of degranulation, 
suggests that this indeed operates via a cytotoxic mechanism (32). Our data further suggest that during 
influenza infection, the inflammatory environment alone can be sufficient for the early up-regulation 
of GzmB, increasing the cytotoxic potential of MAIT cells. Similarly, another study of in vitro culture 
analysis using PBMCs from healthy adults demonstrated that IL-7 cytokine signaling alone can 
induce GzmB and elevate perforin and granzyme A levels in MAIT cells, enhancing their cytolytic 
effector function before bacterial exposure (33). Indeed, another cohort of H7N9 patients analyzed by 
Guo et al. (28) exhibited significantly elevated serum IL-7 levels. Further studies are warranted to 
address the killing potential of MAIT cells during influenza infection. 
Overall, our data show that MAIT cells potently up-regulate antiviral effector molecules, including 
IFNȖ and GzmB, during early IAV infection. This activation is independent of MR1 and is driven by 
soluble inflammatory mediators, including IL-18 produced during influenza infection. This raises the 
possibility that MAIT cells can provide a measure of influenza immunity, even to newly emerging 
influenza viruses such as H7N9, where the host lacks preexisting antigen-specific (T cell and 
antibody) immunity. Perhaps of even more importance, severe influenza disease and lung pathology 
are associated with an increase in secondary or cobacterial infections with respiratory pathogens, 
including Streptococcus pneumoniae, Hemophilus influenzae, Staphylococcus aureus, and, more 
recently, Mycobacterium tuberculosis, identified by surveillance during the 2009 pH1N1 epidemic 
(34, 35). Several of these bacteria use riboflavin pathways, which provide biosynthetic intermediates 
that are metabolized to ligands for MR1 presentation and activation of MAIT cells in a TCR-
dependent manner. Thus, in the setting of concurrent or secondary bacterial infections, MAIT cells 
activated by IAV infection may mediate a potent, “prearmed” antibacterial effector function, 
providing a possible mechanism for promoting protection (or limiting infection) against concurrent 
bacterial infection in severely debilitated patients with pneumonia. 
 
Materials and Methods 
PBMC Isolation. 
After informed consent was obtained, heparinized blood was collected from >30 healthy donors (age 
20–75 y), and PBMCs were isolated by Ficoll-Paque PLUS density-gradient centrifugation. 
Experiments were performed according to the National Health and Medical Research’s code of 
practice and approved by the University of Melbourne Human Ethics Committee (1443389). PBMCs 
from 16 H7N9-infected patients were obtained from Shanghai Public Health Clinic Center, with 
ethics approval by the center’s Ethics Committee (15). 
IAV Infection of A549 Lung Epithelial Cells. 
A549 human lung epithelial cells (American Type Culture Collection) were seeded at 5 × 106 into 
T75 flasks for 24 h before IAV infection. Infection was performed for 1 h with PR8; H1N1 at a 
multiplicity of infection (MOI) of 10–30. Cells were washed and trypsinized before coculture with 
PBMCs. In selected experiments, CD14+ monocytes were enriched from PBMCs using CD14 
magnetic bead enrichment (Miltenyi Biotec). 
Coculture of IAV-Infected A549 Cells with PBMCs. 
Here 1 × 106 PBMCs were cocultured with 2 × 105 IAV-infected or uninfected A549 cells in a 96-
well U-bottomed plate and incubated at 37 °C for 10 h, with the addition of brefeldin A at 3 h. In 
selected experiments, α-MR1 (clone β6.5) at β0 μg/mL or αIL-18 and/or αIL-12 blocking antibodies 
at 5 μg/mL were added at the start of the coculture. Cells were centrifuged, and supernatants were 
removed and stored at −20 °C for CBA analyses. Surface-stained MAIT cells (see below) were fixed 
with Cytofix/Cytoperm (BD Biosciences), washed with Perm/Wash Buffer (BD Biosciences), and 
then incubated with anti–IFN-Ȗ-AF700 (clone B27), anti–TNF-Alexa Fluor 700 (clone MAb11), or 
anti-GzmB (clone GB11, AF700; BD Pharmingen) for 30 min at 4 °C. Cells were washed and then 
analyzed by flow cytometry. 
 
MAIT Cell Analysis. 
Antibodies were obtained from BD Biosciences unless indicated otherwise. MAIT cells were defined 
by the MR1-5-OP-RU tetramer conjugated to SA-Brilliant Violet 421 (BV421) or phycoethryin (PE) 
(1, 5), anti–Vα7.β-allophycocyanin (APC) or PE (3C10; Biolegend), anti-CD161 (BV605; 
Biolegend), anti–CD3-PECF594, or Alexa Fluor 700 (UCHT1). B cells/monocytes were excluded 
based on anti-CD14 APC-H7 (MφP9) and anti-CD19 APC-H7 (HIB19). NK cells and Ȗδ T cells were 
identified by anti-CD56 (NCAM16.2 PE-Cy7) and TCR Ȗδ (βF11, FITC). CD4+ (OKT4 BV650; 
Biolegend) and CD8+ (SK1 PerCP-Cy5.5) cells were included. Dead cells were excluded with 
Live/Dead cell marker (Aqua or Near-Infared; Thermo Fisher Scientific). Then 1 × 106 cells were 
stained in MACS wash buffer (0.5% BSA, 2 mM EDTA) for 30 min, then washed and fixed in 
Cytofix/Cytoperm (BD Biosciences). Samples were acquired on an LSRFortessa cell analyzer (BD 
Biosciences) and analyzed using FlowJo software. 
CBA. 
Culture supernatants were analyzed with a multiplex CBA (BD Biosciences) of 17 analytes: IL-1ȕ, 
IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p40, TNF, MCP-1, MIP-1α, MIP-1ȕ, RANTES, GzmB, IFNα, 
IFNȖ, IL-17A, and FasL. 
  
FIG 1 
 
Reduced numbers of CD161+Vαϳ.Ϯ+ MAIT cells in patients hospitalized with fatal H7N9 disease. (A) Comparison of MAIT cell 
numbers during the course of H7N9 infection in surviving patients (n = 47–81; median, 67.5), fatal patients (n = 56–88; 
median, 68.5), and age-matched controls (n = 52–79; median, 72). (B) MAIT cell numbers across different patient recovery 
groups (R1: recovered days 14–18; R2: days 21–27; R3: days 31–35) and the fatal group (F) during (i) the first week of 
hospitalization (days 6–12 after disease onset), (ii) days 13–20, and (iii) days 21–35. (i) *P = 0.014; (ii and iii) *P = 0.012, 
Kruskal–Wallis test. (C) Representative FACS plots showing CD161+Vαϳ.Ϯ+ MAIT cells during the first week of hospitalization 
across different recovery or fatal groups. MAIT cells were gated on live singlets CD3+CD14−CD19−CD161+Vαϳ.Ϯ+. The number 
of MAIT cells per million PBMCs was calculated as MAIT count × Freq CD3+ × Freq of live lymphocytes × 1 × 106 PBMCs. 
 
 
 
 
 
  
FIG 2 
 
MAIT cells are activated during coculture with IAV-infected lung epithelial cells and PBMCs. (A) Diagram of the coculture 
system. (B) Human lung epithelial cells were infected with IAV-H1N1 at an MOI of 10–30 for 1 h, washed and trypsinized, 
and cocultured with PBMCs for 10 h, followed by intracellular cytokine staining for different immune subsets and activation 
markers. (C) IAV nucleoprotein staining in A549 cells. (DͿ RepƌeseŶtatiǀe FACS plots of IFNɶ aŶd CDϭϬϳa eǆpƌessioŶ iŶ NK, 
MAIT, aŶd ɶɷ T Đells afteƌ PBMC ĐoĐultuƌe ǁith allaŶtoiĐ fluid ;ŵoĐkͿ ;Left), IAV-H1N1–infected A549 cells (Middle), or IAV-
H3N2–infected A549 cells. (EͿ SuŵŵaƌǇ of IFNɶ+pƌoduĐtioŶ afteƌ IAV ĐoĐultuƌe iŶ NK, MAIT, ɶɷ T, CDϰ+, and CD8+cells. n = 
22. ***P < 0.001, ****P < 0.0001, Kruskal–Wallis test. (F and G) Surface CD69 expression (F) and intracellular GzmB (G) are 
up-regulated in MAIT cells after coculture with IAV-infected A549 cells. ***P < 0.001, Wilcoxon rank-sum test. 
  
Fig S1 
 
The gating strategy foƌ MAIT, NK, ɶɷ, CDϰ+, and CD8+ T cells using 12–14 parameter flow cytometery    
 
 
 
  
FIG S2 
 
IFNɶ pƌoduĐtioŶ ďǇ MAIT Đells is highlǇ Đoƌƌelated ǁith NK Đell ;iͿ aŶd ɶɷ T Đell ;iiͿ IFNɶ up-regulation during in vitro 
coculture of PBMCs with IAV-infected A549 cells. Spearman rank correlation. n = 22     
 
  
FIG S3 
 
MAIT cells do not up-regulate TNF production during coculture with IAV-infected lung epithelial cells and PBMCs     
 
  
FIG S4 
 
CD161+Vαϳ.Ϯ+ or MR1-5-OP-RU tetramer+ populations (gated on Live CD3+ cellsͿ ideŶtifǇ the saŵe IFNɶ-producing 
MAIT cells after PBMC coculture with IAV-infected A549 cells. (B) In matched donors, the Pearson correlation 
ĐoeffiĐieŶt ǁas ĐalĐulated foƌ IFNɶ pƌoduĐtioŶ iŶ MAIT Đells, as defiŶed ďǇ eitheƌ the MRϭ-5-OP-RU tetramer+ or 
CD161+Vαϳ.Ϯ+ (n = 8)    
 
 
 
  
Fig 3 
 
Activation of MAIT cells during coculture is not abrogated by MR1-blocking. (AͿ αMRϭ aŶtiďodǇ ǁas added duƌiŶg PBMC 
coculture with IAV-infected epithelial cells or PBMC coculture with 1% paraformaldehyde-fixed E. coli (MOI 0.1) (10). **P < 
0.01, paired t test. n = 4. (B and C) Sort-purified NK cells, but not MAIT cells, can directly respond to IAV-infected human 
luŶg epithelial Đells. IFNɶ aŶd CDϭϬϳa ǁere measured by ICS after 10 h of culture with IAV-infected A549 cells. (D) 
Inflammatory molecule analyses by 17-plex CBA. (i) Supernatants from IAV-infected A549 cells alone). (ii and iii) 
Supernatants from PBMC cocultures with IAV-infected A549 cells. Brefeldin-A was added to cell cultures at 3 h after 
coculture. Total coculture time was 10 h. n = 3     
 
  
FIG 4 
 
MAIT cells are activated by soluble mediators during IAV cocultures. (A) Schematic of supernatant (SN) transfers. (B) (i) 
Representative FACS plots of IFNɶ aŶd GzŵB staiŶiŶg afteƌ IAV Aϱϰϵ:PBMC ĐoĐultuƌe ;Left) or after transfer of SN from 
uninfected (Middle) or infected (Right) to autologous PBMCs in MAIT (Top) or NK (Bottom) cells. (ii and iii) Summary of 
MAIT (ii) and NK (iii) cell SN transfer. *P < Ϭ.Ϭϱ, StudeŶt’s t test. n = 5. (C) IL-18R median fluorescence staining in different 
immune subsets. n = 6. (DͿ αIL-ϭϴ aŶd/oƌ αIL-12p40/70 antibodies were added during PBMC coculture with IAV-infected 
epithelial Đells. Relatiǀe IFNɶ eǆpƌessioŶ iŶ MAIT cells after coculture is shown. *P < 0.05, one-way ANOVA    
   
FIG 5 
 
MoŶoĐǇtes aƌe ƌeƋuiƌed foƌ IFNɶ up-regulation in MAIT cells after IAV infection. (A) TNF production by magnetic bead-
enriched CD14+ monocytes was measured by ICS after 10 h of coculture with IAV-infected A549 cells. **P = 0.0015, 
StudeŶt’s t test. n = 4. (B) (iͿ MoŶoĐǇte depletioŶ fƌoŵ PBMCs ƌesults iŶ aďƌogated NK aŶd MAIT IFNɶ ƌespoŶses duƌiŶg IAV-
infected A549 coculture. (iiͿ IFNɶ pƌoduĐtioŶ as ŵeasuƌed ďǇ ICS iŶ NK aŶd MAIT cells after coculture with monocyte-
depleted or -nondepleted PBMCs + IAV-infected lung epithelial cells. **P = Ϭ.ϬϬϳ, StudeŶt’s t test. n = 5. (C) A model for 
MAIT cell activation during IAV infection  
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